This is part 2, as promised, on what we know about COVID today. This time, I'm talking about prevention.

This deep-dive into the research was inspired when I had it in December which sent me digging through the journals to understand what the science is showing, rather than the misinformation too often heard through media and social media.

In this episode I share:

• Lessons on leadership from these last 4 years


• Putting research reported by the media into perspective


• The current research on Covid prevention including: whether masks work, how dangerous are vaccines, whether boosters are valuable, and a few things you may not have thought about when it comes to prevention.

References for this episode:

Meta-analyses on Masks:

Floriano I, Silvinato A,
Bacha HA, Barbosa AN, Tanni S, Bernardo WM. Effectiveness of wearing masks
during the COVID-19 outbreak in cohort and case-control studies: a systematic
review and meta-analysis. J Bras Pneumol. 2024 Jan 5;49(6):e20230003. doi: 10.36416/1806-3756/e20230003.
PMID: 38198343; PMCID: PMC10760436.

Enright C, Gilbourne C,
Kiersey R, et al. Efficacy of facemasks in preventing transmission of COVID-19
in non-healthcare settings: A scoping review. Journal of Infection Prevention.
2024;25(1-2):24-32. doi:10.1177/17571774231203

Vaccines

Dighriri IM, Alhusayni KM, Mobarki AY, Aljerary
IS, Alqurashi KA, Aljuaid FA, Alamri KA, Mutwalli AA, Maashi NA, Aljohani AM,
Alqarni AM, Alfaqih AE, Moazam SM, Almutairi MN, Almutairi AN. Pfizer-BioNTech
COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review. Cureus. 2022 Mar
26;14(3):e23526. doi: 10.7759/cureus.23526. PMID: 35494952; PMCID: PMC9039171.

S.A. Meo, I.A. Bukhari, J. Akram, A.S. Meo,
D.C. Klonoff ,COVID-19 vaccines: comparison of biological, pharmacological
characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines, Eur
Rev Med Pharmacol Sci, Year: 2021 Vol. 25 - N. 3 Pages: 1663-1669 DOI:
10.26355/eurrev_202102_24877

Rosenblum HG, Hadler SC, Moulia D, Shimabukuro
TT, Su JR, Tepper NK, Ess KC, Woo EJ, Mba-Jonas A, Alimchandani M, Nair N,
Klein NP, Hanson KE, Markowitz LE, Wharton M, McNally VV, Romero JR, Talbot HK,
Lee GM, Daley MF, Mbaeyi SA, Oliver SE. Use of COVID-19 Vaccines After
Reports of Adverse Events Among Adult Recipients of Janssen (Johnson &
Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from
the Advisory Committee on Immunization Practices - United States, July 2021.
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi:
10.15585/mmwr.mm7032e4.

Bishara, H. , Arbel, A. , Barnett-Griness, O. ,
Bloch, S. , Cohen, S. , Najjar-Debbiny, R. , Gronich, N. , Auriel, E. &
Saliba, W. (2023). Association Between Guillain-Barré Syndrome and
COVID-19 Infection and Vaccination. Neurology, 101 (20), e2035-e2042. doi:
10.1212/WNL.0000000000207900

Boosters

Ninaad
Lasrado et al. Waning immunity and IgG4 responses following bivalent mRNA boosting.Sci. Adv.10,eadj9945(2024).DOI:10.1126/sciadv.adj9945

Cheng MQ, Li R, Weng ZY, Song G. Relative
effectiveness of bivalent COVID-19 vaccine: a systematic review and
meta-analysis. Front Med (Lausanne). 2024 Feb 7;10:13 22396. doi:
10.3389/fmed.2023.1322396.

Link-Gelles R, Ciesla AA, Mak J, et al. Early
Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine
Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to
Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing
Community Access to Testing Program, United States, September 2023–January 2024.
(Retrieved Feb 26, 2024) MMWR Morb Mortal Wkly Rep 2024;73:77 –83. DOI: http://dx.doi.org/10.15585/mmwr.mm7304a2

Nasal Spray

Tanori M, Pitaro M, Fratini E, Colantoni E, Amoresano A, Celentano S,
Chiaramonte B, Mancuso M. Safety in Rats of a Novel Nasal Spray Formulation for
the Prevention of Airborne Viral Infections. Pharmaceutics. 2023 Feb
9;15(2):591. doi: 10.3390/pharmaceutics15020591

Dr. Kogan: https://gwcim.com/people/mikhail-kogan-md/

https://www.youtube.com/@DrMishaKogan